Table 1.

Patient	Age	Gende r	Ethnicity	KPS*	IDH	MGMT promoter	Initial surgery	1st line treatment	2nd line treatment	Subsequent lines of treatment	OS**
1	36	female	white	100	wt	unmethylated	STR	RT/TMZ+TMZx4 cycles	Resection followed by indoximod+TMZx2 cycles	Bevacizumab+VB111; re-RT+TMZ+bevacizumab	5.5
2	63	male	white	100	wt	methylated	STR	RT/TMZ+TMZx3 cycles	Indoximod+TMZx3 cycles	Bevacizumab; durvalumab+tremiliimumab; lomustine+bevacizumab	24+
3	46	male	Hispanic	100	wt	unmethylated	GTR	RT/TMZ+TMZ/TTFx3 cycles	Indoximod+TMZx1 cycle	NA	2

KPS, Karnofsky Performance Score; IDH, isocitrate dehydrogenase; wt, wild type; MGMT, methyl-guanine methyl transferase; OS, overall survival; TMZ, temozolomide; TTF, tumor treating fields; RT, radiation therapy; NA, not applicable.

^*at time of initiation of indoximod+temozlomide

^**measured in months from after initiation of indoximod with temozolomide.